Deployment of Transchromosomal Bovine for Personalized Antimicrobial Therapy

Jared N Silver; Cameron D Ashbaugh; Jacob J Miles; Hua Wu; Gregory T Marecki; Joyce K Hwang; Jin-An Jiao; Mark Abrams; Eddie J Sullivan; Duane R Wesemann

doi:10.1093/cid/cix977

Deployment of Transchromosomal Bovine for Personalized Antimicrobial Therapy

Clin Infect Dis. 2018 Mar 19;66(7):1116-1119. doi: 10.1093/cid/cix977.

Authors

Jared N Silver^{1

2}, Cameron D Ashbaugh^{1

2}, Jacob J Miles³, Hua Wu³, Gregory T Marecki^{1

2}, Joyce K Hwang^{1

2}, Jin-An Jiao³, Mark Abrams^{1

2}, Eddie J Sullivan³, Duane R Wesemann^{1

2}

Affiliations

¹ Department of Medicine, Division of Infectious Diseases, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.
² Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.
³ SAb Biotherapeutics Inc, Sioux Falls, South Dakota.

PMID: 29272362
DOI: 10.1093/cid/cix977

Abstract

For decades, intravenous immunoglobulin (IVIg) has provided safe and effective therapy for immunodeficient patients. This proof-of-principle study describes a novel approach to generate personalized IVIg for chronic, antibiotic-resistant infection in real time.

Publication types

Case Reports
Research Support, Non-U.S. Gov't

MeSH terms

Aged
Animals
Anti-Bacterial Agents / therapeutic use*
Biological Therapy*
Cattle
Humans
Immunoglobulins, Intravenous / adverse effects
Immunoglobulins, Intravenous / therapeutic use*
Immunologic Deficiency Syndromes / therapy
Male
Mycoplasma Infections / diagnosis
Mycoplasma Infections / therapy*
Mycoplasma hominis / drug effects
Precision Medicine*
Proof of Concept Study
Surgical Wound Infection / microbiology
Surgical Wound Infection / therapy*

Substances

Anti-Bacterial Agents
Immunoglobulins, Intravenous